Covestor LTD Neurocrine Biosciences Inc Transaction History

Covestor LTD

$150 Million
Q1 2025

A detailed history of Covestor LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Covestor LTD holds 1,752 shares of NBIX stock, worth $214,865. This represents 0.13% of its overall portfolio holdings.

Number of Shares

1,752

Previous 2,011 12.88%

Holding current value

$214,865

Previous $275,000 29.45%

% of portfolio

0.13%

Previous 0.17%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$107.22 - $153.29 $27,769 - $39,702	-259 Reduced 12.88%	1,752 $194,000
Q4 2024 Feb 13, 2025	BUY	$111.62 - $139.44 $25,895 - $32,350	232 Added 13.04%	2,011 $275,000
Q3 2024 Nov 01, 2024	BUY	$114.58 - $153.15 $20,968 - $28,026	183 Added 11.47%	1,779 $205,000
Q2 2024 Aug 09, 2024	SELL	$130.86 - $143.19 $19,367 - $21,192	-148 Reduced 8.49%	1,596 $220,000
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $17,734 - $19,548	136 Added 8.46%	1,744 $241,000
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $86,340 - $108,066	814 Added 102.52%	1,608 $212,000
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $80,105 - $99,769	-852 Reduced 51.76%	794 $89,000
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $80,129 - $93,858	895 Added 119.17%	1,646 $155,000
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $48,937 - $63,970	520 Added 225.11%	751 $76,000
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $11,525 - $13,722	108 Added 87.8%	231 $27,000
Q2 2022 Aug 10, 2022	SELL	$75.79 - $100.07 $19,250 - $25,417	-254 Reduced 67.37%	123 $12,000
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $22,169 - $29,011	306 Added 430.99%	377 $35,000
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $5,655 - $7,541	71 New	71 $6,000

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

97.2M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account